|
haben zu müssen, dass der Krebs zurückkommt, wäre für die Betroffenen ein Segen. Man kann wirklich nur hoffen, dass NeuVax auch die Phase III-Studie erfolgreich abschließt. Aus Anlegersicht glaube ich, dass Galena bis dahin von einem Großen aufgekauft wurde.
10 Potentially Game-Changing Cancer Immunotherapies You Should Be Following
These drugs could become the backbones of cancer treatment for years to come.
"[...]9. NeuVax A cancer immunotherapy underdog of the group could be Galena Biopharma's (NASDAQ:GALE) vaccine NeuVax, which is designed to work as an adjuvant therapy to prevent the recurrence of breast cancer following treatment. In a midstage study that lasted five years, the recurrence rate in the placebo arm was 25.9% compared to just 5.6% in the NeuVax arm -- a 78% clinical benefit. Will the results translate over into a larger trial? That's what we're waiting to find out, as Galena is conducting the phase 3 PRESENT study as we speak. Interim data is due shortly, but the study itself won't be completed until sometime in 2018. If all goes well, Galena's NeuVax could have multiple opportunities to expand its label indications. [...]"
http://www.fool.com/investing/2016/06/02/...ed&utm_source=yahoo-2
NeuVax breast cancer vaccine tested at Memorial Regional Cancer Center
"[...]Dr. Reid is confident that targeted immunotherapy, through vaccines, will one day be cancer's biggest threat. "It's the wave of the future, actually I should say it's the wave of the present and I think the wave of the future as well."
While the NeuVax vaccine is meant to prevent cancer from returning, will we ever have a vaccine so that women never have to worry about even getting the disease? Dr. Reid is optimistic, and he doesn't think it's too far off. "I think so. I think we'll see it going in that direction in the next 15 to 20 years, absolutely. I have a lot of confidence in that.
The NeuVax trial at Memorial is in phase two. It will need to go through phase three before it would get FDA approval." [...]
http://www.wndu.com/content/news/...rial-Cancer-Center-375739991.html
|
Thread abonnieren
ETF-Sparplan